U.S. High Court Won’t Review Discovery Order In Generic Drug MDL
WASHINGTON, D.C. — The U.S. Supreme Court on June 15 denied a motion by generic drug manufacturers to review an antitrust multidistrict litigation court’s order that they produce documents even if...To view the full article, register now.
Already a subscriber? Click here to view full article